NASDAQ:GOSS Gossamer Bio (GOSS) Stock Price, News & Analysis $0.93 +0.02 (+2.20%) (As of 04:16 PM ET) Add Compare Share Share Today's Range$0.90▼$0.9750-Day Range$0.79▼$1.2552-Week Range$0.45▼$1.60Volume532,376 shsAverage Volume1.59 million shsMarket Capitalization$210.39 millionP/E RatioN/ADividend YieldN/APrice Target$9.20 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Gossamer Bio alerts: Email Address Gossamer Bio MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside892.1% Upside$9.20 Price TargetShort InterestHealthy4.23% of Shares Sold ShortDividend StrengthN/ASustainability-0.67Upright™ Environmental ScoreNews Sentiment0.77Based on 3 Articles This WeekInsider TradingAcquiring Shares$249,240 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($0.33) to ($0.74) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.38 out of 5 starsMedical Sector102nd out of 899 stocksPharmaceutical Preparations Industry36th out of 420 stocks 3.5 Analyst's Opinion Consensus RatingGossamer Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageGossamer Bio has only been the subject of 4 research reports in the past 90 days.Read more about Gossamer Bio's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.23% of the outstanding shares of Gossamer Bio have been sold short.Short Interest Ratio / Days to CoverGossamer Bio has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in Gossamer Bio has recently decreased by 0.42%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldGossamer Bio does not currently pay a dividend.Dividend GrowthGossamer Bio does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreGossamer Bio has received a 76.36% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Gossamer Bio is -0.67. Previous Next 3.2 News and Social Media Coverage News SentimentGossamer Bio has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Gossamer Bio this week, compared to 2 articles on an average week.Search InterestOnly 6 people have searched for GOSS on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat Follows5 people have added Gossamer Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Gossamer Bio insiders have bought 19,696.66% more of their company's stock than they have sold. Specifically, they have bought $249,240.00 in company stock and sold $1,259.00 in company stock.Percentage Held by InsidersOnly 5.00% of the stock of Gossamer Bio is held by insiders.Percentage Held by Institutions81.23% of the stock of Gossamer Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Gossamer Bio's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Gossamer Bio are expected to decrease in the coming year, from ($0.33) to ($0.74) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Gossamer Bio is -0.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Gossamer Bio is -0.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGossamer Bio has a P/B Ratio of 3.31. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Gossamer Bio's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Golden CrestBiden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.>> Get Your FREE Wealth Protection Guide << About Gossamer Bio Stock (NASDAQ:GOSS)Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.Read More GOSS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GOSS Stock News HeadlinesSeptember 3, 2024 | americanbankingnews.comQ3 2024 EPS Estimates for Gossamer Bio, Inc. Lifted by HC Wainwright (NASDAQ:GOSS)August 31, 2024 | americanbankingnews.comGossamer Bio (NASDAQ:GOSS) Earns "Buy" Rating from HC WainwrightSeptember 9, 2024 | Golden Crest (Ad)Biden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.August 27, 2024 | stockhouse.comGossamer Bio Announces Data Presentations at the European Respiratory Society Congress 2024August 21, 2024 | finance.yahoo.comAnalysts Just Made A Notable Upgrade To Their Gossamer Bio, Inc. (NASDAQ:GOSS) ForecastsAugust 16, 2024 | msn.comWhat It Takes to Perform Brain SurgeryAugust 16, 2024 | finance.yahoo.comWith 73% institutional ownership, Gossamer Bio, Inc. (NASDAQ:GOSS) is a favorite amongst the big gunsAugust 14, 2024 | markets.businessinsider.comBarclays Reaffirms Their Hold Rating on Gossamer Bio (GOSS)September 9, 2024 | Golden Crest (Ad)Biden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.August 14, 2024 | markets.businessinsider.comBuy Rating Affirmed for Gossamer Bio Amidst Financial Growth and Clinical AdvancementsAugust 13, 2024 | finance.yahoo.comAltPep Corporation Welcomes Denis Sirringhaus as Vice President of Business DevelopmentAugust 13, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Meiragtx Holdings (MGTX), Spruce Biosciences (SPRB) and Gossamer Bio (GOSS)August 13, 2024 | finance.yahoo.comGossamer Bio Announces Second Quarter 2024 Financial Results and Provides Business UpdateAugust 5, 2024 | seekingalpha.comGOSS Gossamer Bio, Inc.July 25, 2024 | msn.comWhy Is Gossamer Bio, Inc. (GOSS) the Best One-Dollar Stock to Buy Now?June 13, 2024 | investorplace.comThe Penny Stock Pundits: 3 Companies Poised to Become the Talk of Wall StreetMay 21, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for Gossamer Bio on Seralutinib’s Promising Clinical Data and Future ProspectsMay 14, 2024 | businesswire.comGossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International ConferenceSee More Headlines Receive GOSS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gossamer Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/12/2024Today9/09/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GOSS CUSIPN/A CIK1728117 Webwww.gossamerbio.com Phone(858) 684-1300FaxN/AEmployees180Year FoundedN/APrice Target and Rating Average Stock Price Target$9.20 High Stock Price Target$15.00 Low Stock Price Target$4.00 Potential Upside/Downside+855.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-179,820,000.00 Net MarginsN/A Pretax Margin-79.73% Return on Equity-117.33% Return on Assets-25.02% Debt Debt-to-Equity Ratio2.42 Current Ratio8.21 Quick Ratio8.21 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.28 per share Price / Book3.44Miscellaneous Outstanding Shares226,230,000Free Float214,908,000Market Cap$217.72 million OptionableOptionable Beta1.95 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Faheem Hasnain (Age 66)Co-Founder, CEO, President & Chairman Comp: $910.26kMr. Bryan Giraudo (Age 49)COO & CFO Comp: $708.09kMr. Robert P. Smith (Age 55)Chief Commercial Officer Comp: $135.79kMr. Christian Waage (Age 57)Executive Vice President of Technical Operations & Administration Comp: $583.16kMr. Jeff BoernekeGeneral Counsel & SecretaryMs. Deanna WeberSenior Vice President of Human ResourcesDr. Richard Aranda M.D. (Age 63)Chief Medical Officer Comp: $625.24kMr. Mario OrlandoSenior Vice President of Commercial New Product PlanningMs. Caryn L. Peterson (Age 65)Executive Vice President of Regulatory Affairs Mr. Matt CravetsSenior Vice President of BiometricsMore ExecutivesKey CompetitorsSinovac BiotechNASDAQ:SVAABIVAX Société AnonymeNASDAQ:ABVXPliant TherapeuticsNASDAQ:PLRX4D Molecular TherapeuticsNASDAQ:FDMTArbutus BiopharmaNASDAQ:ABUSView All CompetitorsInsiders & InstitutionsAlgert Global LLCBought 83,543 shares on 8/16/2024Ownership: 0.037%Millennium Management LLCSold 898,042 shares on 8/15/2024Ownership: 2.474%The Manufacturers Life Insurance Company Bought 124,913 shares on 8/15/2024Ownership: 0.137%NEA Management Company LLCBought 2,255,025 shares on 8/14/2024Ownership: 7.998%Marshall Wace LLPBought 2,103,766 shares on 8/14/2024Ownership: 1.474%View All Insider TransactionsView All Institutional Transactions GOSS Stock Analysis - Frequently Asked Questions How have GOSS shares performed this year? Gossamer Bio's stock was trading at $0.9125 at the beginning of the year. Since then, GOSS shares have increased by 1.6% and is now trading at $0.9273. View the best growth stocks for 2024 here. How were Gossamer Bio's earnings last quarter? Gossamer Bio, Inc. (NASDAQ:GOSS) announced its earnings results on Monday, August, 12th. The company reported $0.22 EPS for the quarter, missing analysts' consensus estimates of $0.23 by $0.01. The company had revenue of $95.84 million for the quarter, compared to analysts' expectations of $160 million. When did Gossamer Bio IPO? Gossamer Bio (GOSS) raised $230 million in an initial public offering (IPO) on Friday, February 8th 2019. The company issued 14,400,000 shares at $16.00 per share. BofA Merrill Lynch, Leerink Partners, Barclays and Evercore ISI served as the underwriters for the IPO. Who are Gossamer Bio's major shareholders? Top institutional shareholders of Gossamer Bio include NEA Management Company LLC (8.00%), Millennium Management LLC (2.47%), Acadian Asset Management LLC (1.59%) and Marshall Wace LLP (1.47%). Insiders that own company stock include Faheem Hasnain, Richard Aranda, Bryan Giraudo, Laura Carter and Caryn Peterson. View institutional ownership trends. How do I buy shares of Gossamer Bio? Shares of GOSS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Gossamer Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Gossamer Bio investors own include Editas Medicine (EDIT), Alector (ALEC), Sorrento Therapeutics (SRNE), Kaleido Biosciences (KLDO), Homology Medicines (FIXX), LogicBio Therapeutics (LOGC) and NVIDIA (NVDA). This page (NASDAQ:GOSS) was last updated on 9/9/2024 by MarketBeat.com Staff From Our PartnersThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredSell NVDA Now?Just weeks before last month’s selloff, Citadel – the most successful hedge fund in history – quietly sold 500...Chaikin Analytics | Sponsored‘Wheels Are Falling Off’ the U.S. Stock Market"Wheels Are Falling Off" The U.S. Stock Market Today, analyst Dan Ferris is back issuing a new warning. He ...Stansberry Research | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredCan Apple’s AI News Make You Rich?September 20th 2024: AI’s “iPhone Moment” Apple is making a major move on Friday, September 20th. And what ...Banyan Hill Publishing | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gossamer Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gossamer Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GOSS Stock Alerts